Evidence of exposure to aristolochic acid in patients with urothelial cancer from a Balkan endemic nephropathy region of Romania

Environmental and Molecular Mutagenesis

Volumn 53, Issue 8, 2012, Pages 636-641

  Schmeiser, Heinz H ^a   Kucab, Jill E ^b,c   Arlt, Volker M ^b   Phillips, David H ^b   Hollstein, Monica ^a,d   Gluhovschi, Gheorghe ^e   Gluhovschi, Cristina ^f   Modilca, Mirela ^g   Daminescu, Liviu ^h   Petrica, Ligia ^f   Velciov, Silvia ^f  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e ACADEMY OF ROMANIAN SCIENTISTS   (Romania)

^f VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^g Dialysis Center Renamed   (Romania)

^h Clinical Emergency County Hospital Pius Brinzeu Timisoara   (Romania)

Author keywords

Aristolochic acid; Balkan endemic nephropathy; DNA adduct; Urothelial cancer

Indexed keywords

ARISTOLOCHIC ACID; DNA; PHOSPHORUS 32;

ADULT; AGED; ARTICLE; AUTORADIOGRAPHY; BALKAN ENDEMIC NEPHROPATHY; BOSNIA AND HERZEGOVINA; CANCER INCIDENCE; CLINICAL ARTICLE; CROATIA; DNA ADDUCT; ENDEMIC DISEASE; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY CARCINOMA; KIDNEY PELVIS CARCINOMA; MALE; MUTAGENICITY; NEPHROTOXICITY; NEPHROURETERECTOMY; ROMANIA; RURAL AREA; SERBIA; TRANSITIONAL CELL CARCINOMA; URETER CARCINOMA; URINARY TRACT CANCER;

AGED; AGED, 80 AND OVER; ARISTOLOCHIC ACIDS; BALKAN NEPHROPATHY; DNA ADDUCTS; FEMALE; HUMANS; KIDNEY; MALE; MIDDLE AGED; MUTATION; ROMANIA; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

ARISTOLOCHIA;

EID: 84867399463     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.21732     Document Type: Article

References (27)

1. Arlt VM, Ferluga D, Stiborova M, Pfohl-Leszkowicz A, Vukelic M, Ceovic S, Schmeiser HH, Cosyns JP. 2002. Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer? Int J Cancer 101: 500-502.
2. Arlt VM, Stiborova M, vom Brocke J, Simoes ML, Lord GM, Nortier JL, Hollstein M, Phillips DH, Schmeiser HH. 2007. Aristolochic acid mutagenesis: Molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogenesis 28: 2253-2261.
3. Bieler CA, Stiborova M, Wiessler M, Cosyns JP, van Ypersele de Strihou C, Schmeiser HH. 1997. 32P-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy. Carcinogenesis 18: 1063-1067.
4. Chen CH, Dickman KG, Moriya M, Zavadil J, Sidorenko VS, Edwards KL, Gnatenko DV, Wu L, Turesky RJ, Wu XR, Pu YS, Grollman AP. 2012. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci USA 109: 8241-8246.
5. Cosyns JP, Goebbels RM, Liberton V, Schmeiser HH, Bieler CA, Bernard AM. 1998. Chinese herbs nephropathy-associated slimming regimen induces tumours in the forestomach but no interstitial nephropathy in rats. Arch Toxicol 72: 738-743.
6. Debelle FD, Vanherweghem JL, Nortier JL. 2008. Aristolochic acid nephropathy: A worldwide problem. Kidney Int 74: 158-169.
7. Gluhovschi G, Margineanu F, Velciov S, Gluhovschi C, Bob F, Petrica L, Bozdog G, Trandafirescu V, Modalca M. 2011. Fifty years of Balkan endemic nephropathy in Romania: Some aspects of the endemic focus in the Mehedinti county. Clin Nephrol 75: 34-48.
8. Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, Suzuki N, Fernandes A, Rosenquist T, Medverec Z, Jakovina K, Brdar B, Slade N, Turesky RJ, Goodenough AK, Rieger R, Vukelic M, Jelakovic B. 2007. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci USA 104: 12129-12134.
9. Hranjec T, Kovac A, Kos J, Mao W, Chen JJ, Grollman AP, Jelakovic B. 2005. Endemic nephropathy: the case for chronic poisoning by aristolochia. Croat Med J 46: 116-125.
10. IARC. 2012. Plants Containing Aristolochic Acid. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. France: IARC. pp 347-361.
11. Ivic M. 1969. Etiology of endemic nephropathy. Lijec Vjesn 91: 1273-1281.
12. Jelakovic B, Karanovic S, Vukovic-Lela I, Miller F, Edwards KL, Nikolic J, Tomic K, Slade N, Brdar B, Turesky RJ, Stipancic Z, Dittrich D, Grollman AP, Dickman KG. 2012. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int 81: 559-567.
13. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C. 2003. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 100: 8424-8429.
14. Kucab JE, Phillips DH, Arlt VM. 2010. Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock-in (Hupki) mouse model. FEBS J 277: 2567-2583.
15. Lord GM, Cook T, Arlt VM, Schmeiser HH, Williams G, Pusey CD. 2001. Urothelial malignant disease and Chinese herbal nephropathy. Lancet 358: 1515-1516.
16. Lord GM, Hollstein M, Arlt VM, Roufosse C, Pusey CD, Cook T, Schmeiser HH. 2004. DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am J Kidney Dis 43: e11-e17.
17. Moriya M, Slade N, Brdar B, Medverec Z, Tomic K, Jelakovic B, Wu L, Truong S, Fernandes A, Grollman AP. 2011. TP53 mutational signature for aristolochic acid: an environmental carcinogen. Int J Cancer 129: 1532-1536.
18. Nedelko T, Arlt VM, Phillips DH, Hollstein M. 2009. TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours. Int J Cancer 124: 987-990.
19. Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, Depierreux MF, De Pauw L, Abramowicz D, Vereerstraeten P, Vanherweghem JL. 2000. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 342: 1686-1692.
20. NTP. 2011. Aristolochic acids. Rep Carcinog 12: 45-49.
21. Olivier M, Hollstein M, Schmeiser HH, Straif K, Wild CP. 2012. Upper urinary tract urothelial cancers: where it's A:T. Nat Rev Cancer 12: 503-504.
22. Schmeiser HH, Bieler CA, Wiessler M, van Ypersele de Strihou C, Cosyns JP. 1996. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res 56: 2025-2028.
23. Schmeiser HH, Janssen JW, Lyons J, Scherf HR, Pfau W, Buchmann A, Bartram CR, Wiessler M. 1990. Aristolochic acid activates ras genes in rat tumors at deoxyadenosine residues. Cancer Res 50: 5464-5469.
24. Schmeiser HH, Stiborova M, Arlt VM. 2009. Chemical and molecular basis of the carcinogenicity of Aristolochia plants. Curr Opin Drug Discov Devel 12: 141-148.
25. Sidorenko VS, Yeo JE, Bonala RR, Johnson F, Scharer OD, Grollman AP. 2012. Lack of recognition by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of aristolactam-DNA adducts. Nucleic Acids Res 40: 2494-2505.
26. Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, Richard C, Vandervelde D, Verbeelen D, Vanhaelen-Fastre R, Vanhaelen M. 1993. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 341: 387-391.
27. Yun BH, Rosenquist TA, Sidorenko V, Iden CR, Chen CH, Pu YS, Bonala R, Johnson F, Dickman KG, Grollman AP, Turesky RJ. 2012. Biomonitoring of Aristolactam-DNA adducts in human tissues using ultra-performance liquid chromatography/ion-trap mass spectrometry. Chem Res Toxicol 25: 1119-1131.